Xiuhua Sun

机构：Dalian Medical University, Second Affiliated Hospital of Dalian Medical University, First Affiliated Hospital of Dalian Medical University, National Institute for Occupational Health and Poison Control · ORCID：0000-0002-5957-0505

发表论文 276 篇 · 总被引 3499 次 · h-index 33

代表论文

• Efficacy and safety of rocbrutinib, a highly selective 4th-generation BTK inhibitor, in Chinese patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) (2025 · Blood · 被引 3)
• Clinical outcomes and therapeutic modalities in older Chinese patients with MCL: a multi-center real-world retrospective study (2025 · Annals of Medicine · 被引 2)
• Safety and Efficacy of Rocbrutinib in Patients with Relapsed/Refractory Marginal Zone Lymphoma (2024 · Blood · 被引 2)
• 61 | A PIVOTAL STUDY OF SHR2554, AN ORAL INHIBITOR AGAINST ENHANCER OF ZESTE HOMOLOG 2 (EZH2), IN RELAPSED OR REFRACTORY (R/R) PERIPHERAL T‐CELL LYMPHOMA (PTCL) (2025 · Hematological Oncology · 被引 1)
• Functional screening of somatic mutant events in extranodal natural killer/T-cell lymphoma with adrenal involvement (2025 · Frontiers in Immunology · 被引 1)
• Supplementary Figure S1 from The Oral PI3Kδ Inhibitor Linperlisib for the Treatment of Relapsed and/or Refractory Follicular Lymphoma: A Phase II, Single-Arm, Open-Label Clinical Trial (2025)